Bloomberg For a masterclass in the upside potential of pharma M&A, look no further than Takeda Pharmaceutical Co.s sale of an eye drug to Novartis AG. By one measure, the deal represents a 2,025% return. Shire Plc, which Takeda bought in January, obtained the assets through a 2013 acquisition. It paid $160 million upfront to gain the late-stage experimental drug, ...

Bloomberg US prosecutors in a high-profile case against Huawei Technologies are seeking to disqualify the company’s lead lawyer, saying he has a conflict of interest stemming from his former role as second-in-command at the Justice Department. James M Cole should be excluded from the Chinese smart-phone maker’s defense team because he had access to classified investigations that appear to be ...

Bloomberg Prices are set to rise for another decade in the world’s least affordable property market, Hong Kong, according to UBS Group AG. Inflows of residents will be key as the Greater Bay Area project integrates a group of mainland Chinese cities with Hong Kong, property analyst John Lam wrote in a research report. The extra buyers will be “more ...